NCT03241264 is a Phase 1 clinical trial of ND-L02-s0201 in Fibrosis, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03241264?

NCT03241264 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03241264?

Interventions in NCT03241264: ND-L02-s0201.

Is NCT03241264 still recruiting?

NCT03241264 is currently completed. Last updated 7 August 2017.

Last reviewed 2017-08-07 · How we verify

NCT03241264

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

Completed Phase 1 Last updated 7 August 2017

What this trial tests

Phase 1 trial testing ND-L02-s0201 in Fibrosis in 12 participants. Completed in 21 October 2016.

Timeline

28 August 2016

Primary endpoint
21 October 2016

21 October 2016

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	12
Start date	28 August 2016
Primary completion	21 October 2016
Estimated completion	21 October 2016

Drugs / interventions tested

ND-L02-s0201

Conditions studied

Fibrosis — all drugs for Fibrosis →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 18 to 55, any sex, with Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and the effects two ND-L02-s0201 have on the body

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, et al · · 2020 · cited 991× · PMID 32561705 · DOI 10.1038/s41392-020-0207-x
Nanoparticles in the clinic: An update.
Anselmo AC, Mitragotri S. · · 2019 · cited 976× · PMID 31572799 · DOI 10.1002/btm2.10143
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.
Dilliard SA, Siegwart DJ. · · 2023 · cited 384× · PMID 36691401 · DOI 10.1038/s41578-022-00529-7
Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246
The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M, Zhang M, Hussain A, Yu X, et al · · 2024 · cited 116× · PMID 38204162 · DOI 10.1016/j.ymthe.2024.01.005
Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications.
Barba AA, Bochicchio S, Dalmoro A, Lamberti G. · · 2019 · cited 76× · PMID 31344836 · DOI 10.3390/pharmaceutics11080360
Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy.
Zhang C, Ma Y, Zhang J, Kuo JC, et al · · 2022 · cited 57× · PMID 35335310 · DOI 10.3390/molecules27061943
Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs.
Gu YY, Liu XS, Lan HY. · · 2024 · cited 25× · PMID 38093516 · DOI 10.1016/j.ymthe.2023.12.009

Verify or expand the search:

Other recruiting trials for Fibrosis

Currently open trials in the same condition.

NCT06912763 — Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-contro · Phase 2 · recruiting
NCT06494111 — Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing · Phase 2 · recruiting
NCT06749522 — Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography Of Fibrosis And Cirrhosis · active not recruiting
NCT05903001 — Diaphragmatic Function as a Biomarker · recruiting
NCT05920226 — Myocardial Fibrosis in Patients With Permanent Pacemakers · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03241264 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 7 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03241264.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing